Maren Hermanns-Clausen (M Hermanns-Clausen)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 6

Top Topics

Intensive Care Unit

Positive Airway Pressure

Acute Respiratory Distress Syndrome

Top Venues

Clinical toxicology (Philadelphia, Pa.)

Archives of toxicology

Drug testing and analysis

This page only lists publications with an associated author ORCID identifier.

Publications

Liesl K Janssens, Michaela J Sommer, Katharina Elisabeth Grafinger, Maren Hermanns-Clausen, Volker Auwärter, Christophe Pol Stove
Interpreting mono- and poly-SCRA intoxications from an activity-based point of view: JWH-018 equivalents in serum as a comparative measure. Archives of toxicology (2024)
Laura Hondebrink, Mark Lawrence Zammit, Lotte C G Hoegberg, Maren Hermanns-Clausen, Davide Lonati, K Faber, null null, null null
Effect of the first wave of COVID-19 on Poison Control Centre activities in 21 European countries: an EAPCCT initiative. Clinical toxicology (Philadelphia, Pa.) 60 (10) (2022)
Michaela J Sommer, Sebastian Halter, Verena Angerer, Volker Auwärter, Florian Eyer, Gesine Liebetrau, Martin Ebbecke, Maren Hermanns-Clausen
Effect of new legislation in Germany on prevalence and harm of synthetic cannabinoids. Clinical toxicology (Philadelphia, Pa.) 60 (10) (2022)
Maren Hermanns-Clausen, Herbert Desel, Elke Färber, Carola Seidel, Angelika Holzer, Florian Eyer, Antje Engel, Dagmar Prasa, Erol Tutdibi, Andreas Stürer
MAGAM II - prospective observational multicentre poisons centres study on eye exposures caused by cleaning products. Clinical toxicology (Philadelphia, Pa.) 57 (9) (2019)
Katharina Koch, Volker Auwärter, Maren Hermanns-Clausen, Maurice Wilde, Merja A Neukamm
Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: Pharmacokinetic data. Drug testing and analysis (2018)
Maren Hermanns-Clausen, Dieter Müller, Josephine Kithinji, Verena Angerer, Florian Franz, Florian Eyer, Hartmud Neurath, Gesine Liebetrau, Volker Auwärter
Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clinical toxicology (Philadelphia, Pa.) 56 (6) (2017)